Darzalex Combos Linked to Stronger Cancer Eradication, Prolonged Survival
Adding Darzalex (daratumumab) to standard regimens for adults with relapsed or refractory multiple myeloma resulted in higher rates of deep and durable responses, according…
Marta Figueiredo, PhD, Managing Science Editor — 
Articles by Marta Figueiredo
Under-the-skin Velcade Found to Work Better in Farydak Triple Combo
Using an under-the-skin formulation of Velcade (bortezomib), in combination with Farydak (panobinostat) and oral dexamethasone, leads to a better safety profile in people…
EU Committee Supports Nexpovio for Heavily Treated Myeloma Patients
A combination of Nexpovio (selinexor) and the corticosteroid dexamethasone has been recommended for conditional approval in the European Union to treat adults with relapsed…
FDA Approval Sought for Cilta-cel CAR T-cell Therapy
Janssen and Legend Biotech are seeking U.S. approval for their investigational CAR T-cell therapy ciltacabtagene autoleucel — known as cilta-cel — to treat adults…
MMRF Joins Dana-Farber to Advance Research in Smoldering Myeloma
The Multiple Myeloma Research Foundation (MMRF) has joined forces with the Dana Farber Cancer Institute to develop new biomarkers and treatments for people with smoldering multiple myeloma (SMM) —…
CLR 131 Elicits Promising Response Rates in Triple-refractory Multiple Myeloma Trial
CLR 131, Cellectar Biosciences’ lead experimental candidate, resulted in a 40% response rate among people with multiple myeloma who failed to respond…
Darzalex Delays Disease Progression After ASCT, Phase 3 Trial Reports
First-line maintenance therapy with Darzalex (daratumumab) significantly delays disease progression or death in adults with multiple myeloma who responded to autologous stem cell transplant (ASCT), according to data…
Ninlaro Combo Fails to Halt Progression of Newly Diagnosed Multiple Myeloma, Trial Data Show
Adding Takeda’s Ninlaro (ixazomib) to Revlimid (lenalidomide) and dexamethasone failed to significantly extend life without disease progression in people newly…
Cilta-cel, CAR T-cell Treatment, Named Breakthrough Therapy in China
Legend Biotech and Janssen’s investigational CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel) has been given breakthrough therapy designation in China as a potential…
FDA Approves Darzalex Triple Combo for Advanced Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab), in combination with Kyprolis (carfilzomib) and dexamethasone, to treat adults with relapsed or…